Partnership to Develop Anticancer Drugs

One (diflomotecan) is the first of a new generation of topoisomerase-1 inhibitors, while the other (BN80927) has a novel mechanism of action that includes dual inhibition of topoisomerases I and II. Beaufour Ipsen is giving worldwide rights, excluding Europe, to these drugs to Roche. Beaufour retains the European rights. In addition, mutual rights have been granted to future follow-on products, the homocamptothecines, a new class of anticancer molecules discovered by Beaufour Ipsen. The two companies will jointly conduct clinical development of the drugs. Roche will pay Beaufour Ipsen up to US$150 million and additional contingent payments.

"We are delighted to be working with such a world-class company and one of the world's leading oncology companies to develop and market novel topoisomerase inhibitors discovered by Beaufour Ipsen,” said Jean-Luc Belingard, CEO of the Beaufour Ipsen Group.





Related Links:
Roche
Beaufour Ipsen